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INTRODUCTION AND OBJECTIVES: Bladder cancer (BC) is a common human malignancy. White light (WL) cystoscopy is the gold standard to detect BC intraoperatively, but up to 30% tumors will be missed, leading to the high recurrence rate of NMIBC. Therefore, we developed a peptide-based probe for NMIBC detection under nearinfrared (NIR) imaging to improve the detection of BC using our technique.
METHODS: In vivo phage display technology was used to select BC targeting peptide (P7) and the peptide was labeled with NIR fluorescein IRDye800CW to synthesize BC specific probe PLSWT7. BC cell lines and orthotopic BC mice model were used to assess the specificity of PLSWT7 in vitro and in vivo. Then twenty patients diagnosed with nonmuscle invasive BC (NMIBC) were enrolled. Following probe intracvesical administration, the entire mucosa was imaged under WL and NIR imaging via our homemade endoscopy that could switch between the two mode. The illuminated lesions under NIR imaging were biopsied and sent for histopathological examination.
RESULTS: The peptide P7 exhibited the highest selectivity among all the phage clones. After labeled with IRDye800CW, the probe PLSWT7 exhibited excellent specificity in vitro and in vivo. After intravesical administration, the probe specifically bound with NMIBC lesions but not normal mucosa or benign lesions in BC patients. Small papillary tumors and carcinoma in situ (CIS) missed under white light imaging were clearly visualized using PLSWT7-DMI fluorescence endoscopy with 91.2% sensitivity and 90% specificity were. The tumor detection rate of PLSWT7-DMI fluorescence endoscopy was 79.4% versus 92.6% for white light imaging.
CONCLUSIONS: We developed a phage display-derived, highly specific probe for BC detection under NIR imaging. Probebased NIR imaging allows the visualization of the missed tumors under WL imaging, thereby improves BC detection rate. This approach holds great potential for clinical translation.
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PD13-07 COMBINATION OF THREE URINARY EXTRACELLULAR VESICLE MRNA BIOMARKERS PREDICTS HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Takahiro Osawa*, Hiroshi Harada, Keita Minami, Nobuo Shinohara, Sapporo, Japan; Taku Murakami, Cindy M. Yamamoto, Irvine, CA; Hiroshi Tanaka, Toshimori Seki, Sapporo, Japan INTRODUCTION AND OBJECTIVES: High-risk non-muscle invasive bladder cancer (HR-NMIBC) (high grade Ta, T1, and any Tis in NCCN category) patients are at higher risk of both recurrence and progression compared to low-risk (LR) NMIBC (low grade Ta). Cystoscopy itself does not allow us to distinguish HR-and LR-NMIBC, therefore pathological analyses of tumors are crucial. The objective of this study is to develop urine based molecular diagnostics to identify and distinguish HR-and LR-NMIBC preoperatively.
METHODS: We conducted a marker discovery using urinary extracellular vesicles (EV) from bladder cancer patients. Candidate markers were identified through RNA-seq analysis of 12 urinary EV from urothelial carcinoma patients, those with a history of urothelial carcinoma and healthy controls. Diagnostic performance of these genes was obtained in a larger cohort of 254 urine samples from urothelial carcinoma patients. EV mRNA were isolated using ExoComplete (Hitachi Chemical Diagnostics, Inc., CA) following the manufacturer's protocol. Statistical analysis was conducted by R and sparse logistic regression analysis (SLR) was employed to identify the coefficients for each gene and cytology and develop scoring formulas for HR-and LR-NMIBC detection.
RESULTS: Among the differentially expressed genes in urinary EV through RNA-seq, we confirmed that SLC2A1 (basal type), GPRC5A (luminal type) and KRT17 (basal type) were elevated in HR-NMIBC (N[74) compared to LR-NMIBC (N[106) by 5.1-fold, 8.6-fold and 4.2-fold, respectively. Indeed, diagnostic performance of these markers was better for HR-NMIBC (AUC 0.739 to 0.802) than those for LR-NMIBC (AUC 0.55 to 0.625). These markers may be useful as prognostic markers since overexpression of these genes in tumors indicated poor prognosis in several types of cancer including renal, liver, pancreatic, lung, and urothelial cancer in the Cancer Genome Atlas (TCGA). Sparse logistic regression analysis through 10-fold cross validation with 50,000 bootstrap re-sampling allowed us to develop scoring formulas comprised of the expression levels of EV SLC2A1, GPRC5A and KRT17 as well as urine cytology with better diagnostic performance (AUC 0.883 for HR-NMIBC, 0.635 for LR-NMIBC) compared to conventional urine cytology alone (AUC 0.785 for HR-NMIBC, 0.504 for LR NMIBC). In addition, this combination was also applicable to detect muscle invasive bladder cancer (MIBC) with AUC 0.830.
CONCLUSIONS: Taken together, our findings suggest that these three urinary EV mRNA were promising biomarkers for risk stratification of NMIBC as well as MIBC.
